3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
3
Recruiting
2
Active not recruiting
2
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Other solid neoplasm
3
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
Cisplatin
30
Pemetrexed
21
Gemcitabine
11
Radiotherapy
6
Nivolumab
6
Drug Therapy
6
Cyclophosphamide
6
Carboplatin
6
durvalumab
4
Vinorelbine
4
Chemotherapy, Adjuvant
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
sodium thiosulfate
3
sargramostim
3
Ipilimumab
3
Doxorubicin
3
raltitrexed
2
pembrolizumab
2
cediranib
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Psychiatric Rehabilitation
2
Photochemotherapy
2
Neoadjuvant Therapy
2
Methotrexate
2
Interferon-alpha
2
Imatinib Mesylate
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma, Malignant
×
Ipilimumab
×
Clear all
NCT05136677
2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2
Completed
102 enrolled
NCT04334759
2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3
Completed
214 enrolled
NCT03048474
2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2
Completed
36 enrolled